Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease

• Published in: Cancer management and research Vol. 10; pp. 7013 - 7019
• Main Authors: Igawa, Satoshi, Nishinarita, Noriko, Takakura, Akira, Ozawa, Takahiro, Harada, Shinya, Kusuhara, Seiichiro, Niwa, Hideyuki, Hosotani, Shinji, Sone, Hideyuki, Nakahara, Yoshiro, Fukui, Tomoya, Mitsufuji, Hisashi, Yokoba, Masanori, Kubota, Masaru, Katagiri, Masato, Sasaki, Jiichiro, Naoki, Katsuhiko
• Format: Journal Article
• Language: English
• Published: New Zealand Taylor & Francis Ltd 01.01.2018; Dove Medical Press
• Subjects: Abdomen; Accuracy; Biopsy; Carboplatin; Chemotherapy; Drug dosages; Hospitals; Interstitial Lung Disease; Lung cancer; Lung diseases; Medical imaging; Medicine; Nab-Paclitaxel; Neutropenia; Neutrophils; NMR; Non-Small cell lung cancer; Nuclear magnetic resonance; Original Research; Patients; Peripheral neuropathy; Pneumonia; Pulmonary fibrosis; Statistical analysis; Tumors; Japan; nab-paclitaxel; interstitial lung disease; carboplatin; non-small-cell lung cancer
• ISSN: 1179-1322; 1179-1322
• DOI: 10.2147/CMAR.S189556

The optimal chemotherapy regimen for non-small-cell lung cancer (NSCLC) patients with interstitial lung disease (ILD) remains unknown. Therefore, in this study, we investigated the real-world efficacy and safety of carboplatin (CBDCA) plus nab-paclitaxel (nab-PTX) as a first-line regimen for NSCLC patients with ILD. We retrospectively reviewed advanced NSCLC patients with ILD who had received CBDCA plus nab-PTX as a first-line chemotherapy regimen between April 2013 and March 2018. Patients were diagnosed with ILD based on the findings of a pretreatment high-resolution computed tomography of the chest. The 34 patients enrolled in this study were included in the efficacy and safety analysis. Collagen vascular disease or a history of exposure to dust or asbestos was not reported for any patients. The median age of patients was 71 years (range, 59-83 years), and 32 patients had a performance status of 0 or 1. The overall response rate was 38.2%. The median progression-free survival and overall survival were 5.8 months and 12.7 months, respectively. Chemotherapy-related acute exacerbation of ILD was observed in two patients (5.7%). Other toxicities were feasible, and no treatment-related deaths occurred. CBDCA plus nab-PTX, as a first-line chemotherapy regimen for NSCLC, showed favorable efficacy and safety in patients with preexisting ILD.